Literature DB >> 29358254

Screening with Papanicolaou tests in Alberta: Are we Choosing Wisely?

Christopher J Symonds1, Wenxin Chen2, Marianne Sarah Rose3, Lara J Cooke4.   

Abstract

OBJECTIVE: To describe the prevalence and geographic distribution of cervical cancer screening, as well as the age groups of those undergoing screening, in Alberta, and to determine if screening practices conform to current guidelines and follow Choosing Wisely Canada recommendations.
DESIGN: Descriptive study using data from the Alberta Ministry of Health Analytics and Performance Reporting Branch.
SETTING: Alberta. PARTICIPANTS: Women who had 1 or more Papanicolaou tests between 2011 and 2013. MAIN OUTCOME MEASURES: Number of women aged 15 to 20 and those aged 70 and older who had 1 or more Pap tests in a 3-year period; year-to-year trends in screening rates for women in these 2 age groups; trends in screening rates in various geographic regions (ie, cities and zones) in Alberta; and the discipline of clinicians who ordered the Pap tests.
RESULTS: Between 2011 and 2013, 805 632 women in the province of Alberta had 1 or more Pap tests for cervical cancer screening. Overall, 25 511 (17.5%) women aged 15 to 20 and 16 818 (10.3%) aged 70 and older were screened contrary to most existing guidelines. Screening rates varied markedly in different geographic regions of the province. Most Pap tests were ordered by family physicians or general practitioners.
CONCLUSION: Within the geographic regions of Alberta, provincial, national, and international guidelines for screening with Pap tests are inconsistently followed. This strongly echoes the need for clinicians and patients to consider the Choosing Wisely Canada recommendations and current guidelines for cervical cancer screening. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Year:  2018        PMID: 29358254      PMCID: PMC5962980     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  16 in total

1.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  Am J Clin Pathol       Date:  2012-04       Impact factor: 2.493

2.  Cervical cancer screening: primum non nocere.

Authors:  Nora Kizer; Jeffrey F Peipert
Journal:  Ann Intern Med       Date:  2012-06-19       Impact factor: 25.391

3.  Pregnancy outcome after cervical cone excision: a case-control study.

Authors:  Katrine Donvold Sjøborg; Ingvild Vistad; Siv S Myhr; Rune Svenningsen; Christine Herzog; Arild Kloster-Jensen; Gunhild Nygård; Sølvi Hole; Tom Tanbo
Journal:  Acta Obstet Gynecol Scand       Date:  2007       Impact factor: 3.636

4.  Recommendations on screening for cervical cancer.

Authors:  James Dickinson; Eva Tsakonas; Sarah Conner Gorber; Gabriela Lewin; Elizabeth Shaw; Harminder Singh; Michel Joffres; Richard Birtwhistle; Marcello Tonelli; Verna Mai; Meg McLachlin
Journal:  CMAJ       Date:  2013-01-07       Impact factor: 8.262

5.  The association between cervical cancer screening and mortality from cervical cancer: a population based case-control study.

Authors:  Danielle Vicus; Rinku Sutradhar; Yan Lu; Laurie Elit; Rachel Kupets; Lawrence Paszat
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

6.  The effect of loop electrosurgical excision procedure on future pregnancy outcome.

Authors:  Sheri-Lee A Samson; James R Bentley; T John Fahey; Deanna J McKay; Glenn H Gill
Journal:  Obstet Gynecol       Date:  2005-02       Impact factor: 7.661

7.  Association between cervical screening and prevention of invasive cervical cancer in Ontario: a population-based case-control study.

Authors:  Danielle Vicus; Rinku Sutradhar; Yan Lu; Rachel Kupets; Lawrence Paszat
Journal:  Int J Gynecol Cancer       Date:  2015-01       Impact factor: 3.437

8.  Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.

Authors:  Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Meg Watson; Douglas R Lowy; Lauri E Markowitz
Journal:  Vaccine       Date:  2012-08-04       Impact factor: 3.641

9.  Loop electrosurgical excision procedure and the risk for preterm delivery.

Authors:  Annu Heinonen; Mika Gissler; Annika Riska; Jorma Paavonen; Anna-Maija Tapper; Maija Jakobsson
Journal:  Obstet Gynecol       Date:  2013-05       Impact factor: 7.661

10.  Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006.

Authors:  James A Dickinson; Agata Stankiewicz; Cathy Popadiuk; Lisa Pogany; Jay Onysko; Anthony B Miller
Journal:  BMC Public Health       Date:  2012-11-16       Impact factor: 3.295

View more
  2 in total

1.  Inappropriate use of clinical practices in Canada: a systematic review.

Authors:  Janet E Squires; Danielle Cho-Young; Laura D Aloisio; Robert Bell; Stephen Bornstein; Susan E Brien; Simon Decary; Melissa Demery Varin; Mark Dobrow; Carole A Estabrooks; Ian D Graham; Megan Greenough; Doris Grinspun; Michael Hillmer; Tanya Horsley; Jiale Hu; Alan Katz; Christina Krause; John Lavis; Wendy Levinson; Adrian Levy; Michelina Mancuso; Steve Morgan; Letitia Nadalin-Penno; Andrew Neuner; Tamara Rader; Wilmer J Santos; Gary Teare; Joshua Tepper; Amanda Vandyk; Michael Wilson; Jeremy M Grimshaw
Journal:  CMAJ       Date:  2022-02-28       Impact factor: 16.859

2.  Cervical Screening Practices and Outcomes for Young Women in Response to Changed Guidelines in Calgary, Canada, 2007-2016.

Authors:  Sayeeda Amber Sayed; Christopher Naugler; Guanmin Chen; James A Dickinson
Journal:  J Low Genit Tract Dis       Date:  2021-01-01       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.